2008 Independent Satellite Symposia at the Annual Meeting - ASCO

Home > Abstracts & Virtual Meeting > Independent Satellite Symposia > 2008 Independent Satellite Symposia at the Annual Meeting

2008 Independent Satellite Symposia at the Annual Meeting

These events were not part of the official ASCO Annual Meeting program. The content and views expressed are those of the educational sponsor and faculty and not of ASCO.

Advances in Lymphoproliferative Disease: From Molecular Pathogenesis to Multitargeted Treatment
Supported by: Celgene, Cephalon, and Millennium

Attacking the Signal at the Switch: Unraveling the Mysteries of mTOR Inhibition in Multiple Tumor Types
Supported by: Novartis

Bench to Bedside: Innovative approaches to Hematologic Malignancies
Supported by: Celgene

Building Better Strategies To Manage Melanoma: Clinical Controversies and Opportunities to Optimize Outcomes
Supported by: Schering-Plough

Challenging the Current Concepts of Multiple Myeloma Treatment in an Era of Novel Therapies
Supported by: Multiple Myeloma Research Foundation

Contemporary Strategies for Abrogating Immunologic Tolerance to Melanoma
Supported by: Bristol-Myers Squibb

Developmental Therapeutics in Advanced Breast Cancer: Novel Mechanisms and Future Directions
Supported by: Eisai, Inc.

From Signal Transduction to Epigenetic Regulation of Gene Expression in Oncology: Challenging Clinical Cases
Supported by: Merck

Key questions in metastatic colorectal cancer: The experts respond
Supported by: Bristol-Myers Squibb and ImClone Systems, Inc.

New Therapeutic Options for Challenging Hematologic Diseases
Supported by: Celgene and Alexion Pharmaceuticals, Inc.

Patient Management in the Era of Targeted Therapy: Four Interactive Case Presentations
Supported by: Novartis

Personalizing the Treatment of Solid Malignancies with Taxane-Based Therapies
Supported by: Abraxis, AstraZeneca, and Genomic Health

Progress Toward a Continuum of Care for Patients with Lung Cancer
Supported by: Genentech

Receptor-Based Therapeutics: An Interactive Exposé
Supported by: GlaxoSmithKline